You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Millimeter-wave Tunable Cavity for Ultra-sensitive Solids and Liquids DNP-NMR at Low Budget

    SBC: DOTY SCIENTIFIC, INC.            Topic: NIA

    ? DESCRIPTION (provided by applicant): NMR is probably the most powerful and widely used analytical technique for structure determination and function elucidation of molecules of all types, but it suffers from low sensitivity, particularly for insoluble biological macromolecules. Dynamic Nuclear Polarization (DNP) with Magic Angle Spinning (MAS) has recently demonstrated S/N gains exceeding t ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. A Rapid assay for RNA targeted drugs: Instrumentation Supplement

    SBC: NUBAD LLC            Topic: 300

    DESCRIPTION provided by applicant Some of the most significant therapies that treat disease target nucleic acids Drugs that target nucleic acid include cancer drugs antibiotics and antivirals Combined these classes of drugs have annual sales worldwide of $ billion Antibiotics that target nucleic acids account for $ billion of the $ billion of sales annuall for all antibiotics an ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Assessing the Bite Counter as a Tool for Food Intake Monitoring: Phase II

    SBC: BITE TECHNOLOGIES, LLC            Topic: 300

    DESCRIPTION provided by applicant Self monitoring has been described as the andquot cornerstone of the behavioral treatment of obesityandquot Consistent self monitoring of energy intake is associated with improved dietary adherence and weight loss and maintenance The problem is that individuals are notoriously bad at self monitoring their intake and suffer from an underreporting bias The s ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian Cancer

    SBC: THERATARGET, INC.            Topic: NCI

    DESCRIPTION provided by applicant The purpose of this Phase II STTR project is to develop a polymeric system for the combination delivery of two antineoplastic agents gemcitabine and paclitaxel Based on the successful results of the STTR Phase I award this Phase II proposal details the rationale and research plan for the synthesis and evaluation of in vivo efficacy of two novel macromolecula ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Computer-based Prescription Opioid Abuse Prevention for Adolescents

    SBC: HEALTHSIM, INC.            Topic: R42

    DESCRIPTION provided by applicant Recreational use of prescription opioids among adolescents is a significant and growing public health concern and has been referred to as an emerging epidemic in the U S Although a number of science based interactive drug abuse prevention programs exist focused on preventing use of non prescription drugs among youth to our knowledge no science based inter ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development and in vitro validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 105

    DESCRIPTION provided by applicant Sanfilippo disease mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which plays importa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Development of an Antigen Capture Assay for Babesia microti

    SBC: BIOPEPTIDES CORP            Topic: NIAID

    DESCRIPTION provided by applicant Babesia microti the primary etiologic agent of human babesiosis is a tick borne eukaryotic apicomplexan pathogen that is an increasing threat to the US public health Although B microti is primarily a tick borne pathogen it can be transmitted by transfusion of infected blood Despite the well recognized threat there is no FDA licensed test to screen donor ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a new approach to screening for language impairments

    SBC: PANTHER TECHNOLOGY            Topic: NIDCD

    DESCRIPTIONprovided by applicantThis Small Business Technology and TransferSTTRFast Track proposal focuses on the translation of innovative research protocols for diagnosing Specific Language ImpairmentSLIinto an innovativeeasy touse app based screener with high potential for private sector commercializationSLI is a form of language impairment with no known causewith a strong research baseBecause ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Development of Peptide Antibiotic Nucleic Acids

    SBC: NUBAD LLC            Topic: NIAID

    DESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Evaluation of TRB-N0224, a Proprietary Chemically-Modified Curumin, for the Treat

    SBC: TRAVERSE BIOSCIENCES, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): Traverse Biosciences Inc. is a pre-clinical stage drug development company working to commercialize new chemical entities which act to resolve inflammatory conditions through pleiotropic host-modulation of pathologically unrestrained matrix metalloproteinases (MMPs) and pro-inflammatory cytokines. The company's lead drug candidate, TRB-N0224, is a proprie ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government